Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Geneos Therapeutics Presents Personalized Neoantigen-Based DNA Therapy That Sustains Anti-tumor Immunity in Brain Cancer Patients and Offers a Path to Dynamic Therapy

      Geneos Logo

      News provided by

      Geneos Therapeutics, Inc.

      Nov 16, 2026, 08:30 ET

      Share this article

      Share this article


      PHILADELPHIA, Nov. 16, 2026 /PRNewswire/ -- Geneos Therapeutics, a clinical stage biotherapeutics company focused on the development of neoantigen-targeted personalized DNA immunotherapy for cancer (PIC), presented follow-up data from extended treatment of two patients with high grade glioma which demonstrates the feasibility of sustained immune surveillance and dynamic therapy in clinical practice. These data were presented (Abstract #CTIM-23) at the 31st Society for Neuro-Oncology (SNO) Annual Meeting in Philadelphia, PA by Tanner Johanns, MD, PhD, Assistant Professor of Medicine, Division of Medical Oncology, Washington University School of Medicine.

      The first of the two patients was a newly diagnosed MGMT-unmethylated glioblastoma patient on Geneos' GT-20 trial [NCT04015700] who received 19 doses of PIC (encoding 38 neoantigens) over five years. The PIC immunotherapy followed her standard of care surgery and radiation, and she is progression-free five years after diagnosis. While the patient's brain images showed signs consistent with disease progression at 1.7, 2.2, and 3 years, the lesions largely resolved, while receiving PIC treatment alone. Immunological and histological characterization of the patient's on-treatment brain tissue and blood samples showed newly emergent CD8+ T cell clones found in both the blood and the brain, indicating that the extended PIC treatment may have been associated with active immune surveillance, thereby preventing the patient's cancer from recurring.

      The second case, a patient with anaplastic astrocytoma treated under a compassionate use protocol, received neoantigen-based "dynamic" therapy in which personalized treatments were iteratively redesigned as more information became available to target tumor-derived neoantigens. The patient was treated with three successive PIC generations encoding increasing neoantigen repertoires (30, 36, 43 neoantigens). She received standard of care surgery, radiation and temozolomide in year one, followed by 20 doses of PIC over seven years, and remains progression-free over eight years since initial surgery. Similar to the first patient, brain scans also showed signs consistent with disease progression at 1.5 and 2 years that resolved on their own while remaining on PIC treatment. This patient also developed robust, polyfunctional T cell responses to the PIC neoantigens for each of the three generations, supporting dynamic neoantigen targeting as a strategy to address tumor evolution while sustaining anti-tumor immunity.

      "The two patients represent the first cases of extended treatment with a personalized cancer vaccine in patients with brain cancer," said Dr. Johanns. "The potential to tailor the patient's treatment as new information becomes available, as in the second case, is tremendously exciting. Current approaches are typically static and do not account for spatial heterogeneity or the emergence of newly dominant tumor clones during treatment. Geneos' ability to dynamically customize the vaccine to the evolving tumor is a crucial step forward for the field of cancer vaccination."

      "It is gratifying to see these data showing that iterative tumor profiling and sequential vaccine design may extend the principle of personalized immunotherapy from a static, one-time intervention to a dynamic treatment strategy. A key advantage to our PIC platform is our straightforward manufacturing process and fast turnaround time which allows real-time incorporation of newly identified neoantigens into subsequent DNA vaccine design and treatment," said Niranjan Sardesai, PhD, Founder, President and CEO of Geneos Therapeutics. "We are not far from a future where personalized DNA dynamic therapy could be used to treat tumors that escape, ultimately providing patients with durable clinical benefit."

      About Personalized DNA Immunotherapy for Cancer (PIC)

      PICs are patient-specific treatments based on DNA plasmids that encode up to 40 tumor neoantigens on a single DNA plasmid. A patient's tumor is sequenced to identify the neoantigens used to develop a personalized DNA cancer vaccine. Treatment with PICs trains the patient's immune cells to produce cancer targeting CD4 and CD8 T cells that destroy the cancer cells. PICs mechanism of action is cancer agnostic, and the platform supports seamless expansion into other cancers beyond glioblastoma.

      About Glioblastoma and High-Grade Gliomas
      Glioma is a broad term for any brain or spinal cord tumor that starts in glial cells. High-grade gliomas are any grade 3 or grade 4 gliomas. Glioblastoma, a specific and very aggressive type of grade 4 glioma, is the most aggressive primary malignant brain tumor in adults. Despite extensive research and advances in molecular diagnostics and supportive care, median survival ranges from 12 to 18 months. Therapeutic failures reflect biological and anatomical barriers, an immunosuppressive tumor microenvironment, intratumoral heterogeneity, infiltrative growth, and restricted drug delivery across the blood-brain barrier.

      About Geneos Therapeutics
      Geneos Therapeutics is a Phase 2 clinical-stage biotherapeutics company developing personalized immunotherapies for cancer (PICs). The company's approach uses its proprietary DNA-based GT-EPIC™ platform to target neoantigens (abnormal mutations produced by cancer cells) from individual patient tumors to develop novel and uniquely personalized DNA immunotherapies for cancer. For more information, please visit www.geneostx.com, and follow on LinkedIn.

      This press release contains certain forward-looking statements relating to our business, including our plans regarding the development of neoantigen-based personalized immunotherapies for cancer, our expectations regarding our research and development programs, including the planned expansion and conduct of clinical trials. Actual events or results may differ from the expectations set forth herein. There can be no assurance that any product candidate in Geneos' pipeline will be successfully developed, manufactured or commercialized, that final results of clinical trials will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate. Forward-looking statements speak only as of the date of this release, and Geneos undertakes no obligation to update or revise these statements, except as may be required by law.

      Media Contact:

      Jennifer Williams
      Cook Williams Communications, Inc.
      [email protected]

      SOURCE Geneos Therapeutics, Inc.

      Modal title

      Also from this source

      Geneos Therapeutics Announces Scientific Meeting Presentation of Sustained Immunosurveillance and Progression-free Survival in Two Brain Cancer Patients Treated with Neoantigen Targeted Personalized DNA Immunotherapy

      Geneos Therapeutics Announces Scientific Meeting Presentation of Sustained Immunosurveillance and Progression-free Survival in Two Brain Cancer Patients Treated with Neoantigen Targeted Personalized DNA Immunotherapy

      Geneos Therapeutics, a clinical stage biotherapeutics company focused on the development of neoantigen targeted personalized DNA immunotherapy for...

      Geneos Therapeutics Initiates IMPACT31 Phase 2 Randomized Clinical Trial Evaluating Neoantigen-Targeted Personalized DNA Immunotherapy for Cancer

      Geneos Therapeutics Initiates IMPACT31 Phase 2 Randomized Clinical Trial Evaluating Neoantigen-Targeted Personalized DNA Immunotherapy for Cancer

      Geneos Therapeutics, a clinical stage biotherapeutics company focused on the development of neoantigen-based personalized immunotherapy for cancer...

      More Releases From This Source

      Explore

      Health Care & Hospitals

      Health Care & Hospitals

      Pharmaceuticals

      Pharmaceuticals

      Biotechnology

      Biotechnology

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.